Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND IgA nephropathy is a chronic immune-mediated kidney disease and a major cause of kidney failure worldwide. The gut mucosal immune system is implicated in its pathogenesis, and Nefecon is a novel, oral, targeted-release formulation of budesonide designed to act at the gut mucosal level. We present findings from the 2-year, phase 3 NefIgArd trial of Nefecon in patients with IgA nephropathy. METHODS In this phase 3, multicentre, randomised, double-blind, placebo-controlled trial, adult patients (aged ≥18 years) with primary IgA nephropathy, estimated glomerular filtration rate (eGFR) 35-90 mL/min per 1·73 m2, and persistent proteinuria (urine protein-creatinine ratio ≥0·8 g/g or proteinuria ≥1 g/24 h) despite optimised renin-angiotensin system blockade were enrolled at 132 hospital-based clinical sites in 20 countries worldwide. Patients were randomly assigned (1:1) to receive 16 mg/day oral capsules of Nefecon or matching placebo for 9 months, followed by a 15-month observational follow-up period off study drug. Randomisation via an interactive response technology system was stratified according to baseline proteinuria (<2 or ≥2 g/24 h), baseline eGFR (<60 or ≥60 mL/min per 1·73 m2), and region (Asia-Pacific, Europe, North America, or South America). Patients, investigators, and site staff were masked to treatment assignment throughout the 2-year trial. Optimised supportive care was also continued throughout the trial. The primary efficacy endpoint was time-weighted average of eGFR over 2 years. Efficacy and safety analyses were done in the full analysis set (ie, all randomly assigned patients). The trial was registered on ClinicalTrials.gov, NCT03643965, and is completed. FINDINGS Patients were recruited to the NefIgArd trial between Sept 5, 2018, and Jan 20, 2021, with 364 patients (182 per treatment group) randomly assigned in the full analysis set. 240 (66%) patients were men and 124 (34%) were women, and 275 (76%) identified as White. The time-weighted average of eGFR over 2 years showed a statistically significant treatment benefit with Nefecon versus placebo (difference 5·05 mL/min per 1·73 m2 [95% CI 3·24 to 7·38], p<0·0001), with a time-weighted average change of -2·47 mL/min per 1·73 m2 (95% CI -3·88 to -1·02) reported with Nefecon and -7·52 mL/min per 1·73 m2 (-8·83 to -6·18) reported with placebo. The most commonly reported treatment-emergent adverse events during treatment with Nefecon were peripheral oedema (31 [17%] patients, vs placebo, seven [4%] patients), hypertension (22 [12%] vs six [3%]), muscle spasms (22 [12%] vs seven [4%]), acne (20 [11%] vs two [1%]), and headache (19 [10%] vs 14 [8%]). No treatment-related deaths were reported. INTERPRETATION A 9-month treatment period with Nefecon provided a clinically relevant reduction in eGFR decline and a durable reduction in proteinuria versus placebo, providing support for a disease-modifying effect in patients with IgA nephropathy. Nefecon was also well tolerated, with a safety profile as expected for a locally acting oral budesonide product. FUNDING Calliditas Therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216655 · Cited by 2,710
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationWyatt, R. J., & Julian, B. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1206793 · Cited by 1,222
KDIGO Clinical Practice Guideline for Glomerulonephritis
Eckardt, K., & Kasiske, B. L. (2012) · Cited by 894
Intensive supportive care plus immunosuppression in IgA nephropathy
Rauen, T., Eitner, F., Fitzner, C., Sommerer, C., Zeier, M., Otte, B., Panzer, U., Peters, H., Benck, U., Mertens, P. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415463 · Cited by 726
Self-citationLai, K. N., Tang, S. C. W., Schena, F. P., Novak, J., Tomino, Y., Fogo, A. B., & Glassock, R. J. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.1 · Cited by 508
Long-Term Outcomes in IgA Nephropathy
Pitcher, D., Braddon, F., Hendry, B., Mercer, A., Osmaston, K., Saleem, M. A., Steenkamp, R., Wong, K., Turner, A. N., Wang, K., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000135 · Cited by 458
Self-citationFellström, B. C., Barratt, J., Cook, H., Coppo, R., Feehally, J., de Fijter, J. W., Floege, J., Hetzel, G., Jardine, A. G., Locatelli, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30550-0 · Cited by 414
Self-citationLv, J., Wong, M. G., Hladunewich, M. A., Jha, V., Hooi, L. S., Monaghan, H., Zhao, M., Barbour, S., Jardine, M. J., Reich, H. N., et al. (2022) · JAMA · doi:10.1001/jama.2022.5368 · Cited by 354
Self-citationInker, L. A., Heerspink, H. J. L., Tighiouart, H., Levey, A. S., Coresh, J., Gansevoort, R. T., Simon, A. L., Ying, J., Beck, G. J., Wanner, C., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019010007 · Cited by 310
Self-citationMice overexpressing BAFF develop a commensal flora–dependent, IgA-associated nephropathy
McCarthy, D. D., Kujawa, J., Wilson, C., Papandile, A., Poreci, U., Porfilio, E. A., Ward, L., Lawson, M. A. E., Macpherson, A. J., McCoy, K. D., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45563 · Cited by 286
Prognosis in IgA Nephropathy: 30-Year Analysis of 1,012 Patients at a Single Center in Japan
Moriyama, T., Tanaka, K., Iwasaki, C., Oshima, Y., Ochi, A., Kataoka, H., Itabashi, M., Takei, T., Uchida, K., & Nitta, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091756 · Cited by 259
The genetics and immunobiology of IgA nephropathy
Kiryluk, K., & Novak, J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74475 · Cited by 224
Barratt, J., Lafayette, R., Kristensen, J., Stone, A., Cattran, D., Floege, J., Tesar, V., Trimarchi, H., Zhang, H., Eren, N., et al. (2023) · Kidney International · doi:10.1016/j.kint.2022.09.017 · Cited by 224
Self-citationAn update on the pathogenesis and treatment of IgA nephropathy
Boyd, J. K., Cheung, C. K., Molyneux, K., Feehally, J., & Barratt, J. (2012) · Kidney International · doi:10.1038/ki.2011.501 · Cited by 164
Self-citationThe Gut-Renal Connection in IgA Nephropathy
Coppo, R. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.05.020 · Cited by 140
Smerud, H. K., Barany, P. F., Lindstrom, K., Fernström, A., Sandell, A., Påhlsson, P., & Fellström, B. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr052 · Cited by 139
Immunosuppressive agents for treating IgA nephropathy
Vecchio, M., Bonerba, B., Palmer, S. C., Craig, J. C., Ruospo, M., Samuels, J., Molony, D. A., Schena, F. P., & Strippoli, G. F. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003965.pub2 · Cited by 119
Why Target the Gut to Treat IgA Nephropathy?
Barratt, J., Rovin, B. H., Cattran, D., Floege, J., Lafayette, R., Tesar, V., Trimarchi, H., & Zhang, H. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.08.009 · Cited by 95
Self-citationOne-Year estimated GFR Slope Independently Predicts Clinical Benefit in Immunoglobulin A Nephropathy
Lafayette, R. A., Reich, H. N., Stone, A. M., & Barratt, J. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.09.017 · Cited by 20
Self-citationRecent advances in the understanding and management of IgA nephropathy
Lai, K. N., Leung, J. C. K., & Tang, S. C. W. (2016) · F1000Research · doi:10.12688/f1000research.7352.1 · Cited by 16
Cited by
Rovin, B. H., Barratt, J., Heerspink, H. J. L., Alpers, C. E., Bieler, S., Chae, D.-W., Diva, U. A., Floege, J., Gesualdo, L., Inrig, J. K., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)02302-4 · Cited by 307
Self-citationA Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
Mathur, M., Barratt, J., Chacko, B., Chan, T. M., Kooienga, L., Oh, K.-H., Sahay, M., Suzuki, Y., Wong, M. G., Yarbrough, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2305635 · Cited by 239
Self-citationThe pathogenesis of IgA nephropathy and implications for treatment
Cheung, C. K., Alexander, S., Reich, H. N., Selvaskandan, H., Zhang, H., & Barratt, J. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00885-3 · Cited by 222
Self-citationRovin, B. H., Barratt, J., Cook, H. T., Noronha, I. L., Reich, H. N., Suzuki, Y., Tang, S. C. W., Trimarch, H., & Floege, J. (2025) · Kidney International · doi:10.1016/j.kint.2025.04.004 · Cited by 206
Self-citationAlternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
Perkovic, V., Barratt, J., Rovin, B., Kashihara, N., Maes, B., Zhang, H., Trimarchi, H., Kollins, D., Papachristofi, O., Jacinto-Sanders, S., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410316 · Cited by 197
Self-citation
Metadata
- Authors
- Lafayette, R., Kristensen, J., Stone, A., Floege, J., Tesař, V., Trimarchi, H., Zhang, H., Eren, N., Paliege, A., Reich, H. N., Rovin, B. H., & Barratt, J.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 402
- Issue
- 10405
- Pages
- 859-870
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4385803938
- Cited by
- 337
- References
- 24
- FWCI
- 55.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.